The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.
 
Marcia S. Brose
Honoraria - Bayer; Eisai; Lilly
Consulting or Advisory Role - AADi; Bayer; Eisai; Exelixis; Lilly; Loxo
Research Funding - Lilly (Inst); Loxo (Inst)
 
C. Benedikt Westphalen
Honoraria - Bayer; GlaxoSmithKline; Ipsen; Merck Serono; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Consulting or Advisory Role - BMS; Celgene; MSD; Rafael Pharmaceuticals; RedHill Biopharma; Roche; Shire
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bayer; Celgene; Halozyme; RedHill Biopharma; Roche; SERVIER; Taiho Pharmaceutical
 
Kenneth L. Kehl
Employment - Change Healthcare (I); OptumRx (I)
 
Xiaoyun Pan
Employment - Bayer
 
Vadim Bernard-Gauthier
Employment - Bayer
 
Milena Kurtinecz
Employment - Bayer
 
Helen Guo
Employment - Bayer
 
Virginie Aris
Employment - Bayer
 
Neil R. Brett
Employment - PPD, part of Thermo Fisher Scientific
 
Abdelali (Ali) MAJDI
Employment - Bayer
 
Vivek Subbiah
Consulting or Advisory Role - Bayer (Inst); Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Clinical Care Options; Medscape
 
Nathan A. Pennell
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Genentech; Iovance Biotherapeutics; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Picture Health; ResistanceBio; Sanofi/Regeneron; Summit Therapeutics; Takeda; Vial
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Navire (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Summit pharmaceuticals (Inst)
 
Alexander E. Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva